BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18414863)

  • 1. Cytogenetic features in myelodysplastic syndromes.
    Haase D
    Ann Hematol; 2008 Jul; 87(7):515-26. PubMed ID: 18414863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic abnormalities in myelodysplastic syndrome: an overview.
    Kawankar N; Vundinti BR
    Hematology; 2011 May; 16(3):131-8. PubMed ID: 21669051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosomal aberrations in myelodysplastic syndrome].
    Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
    Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes.
    Billström R; Thiede T; Hansen S; Heim S; Kristoffersson U; Mandahl N; Mitelman F
    Eur J Haematol; 1988 Oct; 41(4):341-6. PubMed ID: 3197821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic findings in 179 patients with myelodysplastic syndromes.
    Haase D; Fonatsch C; Freund M; Wörmann B; Bodenstein H; Bartels H; Stollmann-Gibbels B; Lengfelder E
    Ann Hematol; 1995 Apr; 70(4):171-87. PubMed ID: 7748962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
    Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
    Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
    Kantarjian H; O'Brien S; Ravandi F; Borthakur G; Faderl S; Bueso-Ramos C; Abruzzo L; Pierce S; Shan J; Issa JP; Garcia-Manero G
    Cancer; 2009 Nov; 115(22):5202-9. PubMed ID: 19691096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
    Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
    Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment options: impact of cytogenetics on the course of myelodysplasia.
    Galili N; Cerny J; Raza A
    Curr Treat Options Oncol; 2007 Apr; 8(2):117-28. PubMed ID: 17634837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
    J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
    Ganster C; Müller-Thomas C; Haferlach C; Strupp C; Ogata K; Germing U; Hildebrandt B; Mallo M; Lübbert M; Müller C; Solé F; Götze KS; Vandenberghe P; Göhring G; Steinmetz T; Kröger N; Platzbecker U; Söling U; Raynaud S; Shirneshan K; Schanz J; Haase D
    Genes Chromosomes Cancer; 2019 Oct; 58(10):689-697. PubMed ID: 30994215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics.
    Trost D; Hildebrandt B; Müller N; Germing U; Royer-Pokora B
    Leuk Res; 2004 Feb; 28(2):171-7. PubMed ID: 14654082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
    Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
    Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.